An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease

AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomiz...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Süssmuth, Sigurd D, Haider, Salman, Landwehrmeyer, G Bernhard, Farmer, Ruth, Frost, Chris, Tripepi, Giovanna, Andersen, Claus A, Di Bacco, Marco, Lamanna, Claudia, Diodato, Enrica, Massai, Luisa, Diamanti, Daniela, Mori, Elisa, Magnoni, Letizia, Dreyhaupt, Jens, Schiefele, Karin, Craufurd, David, Saft, Carsten, Rudzinska, Monika, Ryglewicz, Danuta, Orth, Michael, Brzozy, Sebastian, Baran, Anna, Pollio, Giuseppe, Andre, Ralph, Tabrizi, Sarah J, Darpo, Borje, Westerberg, Goran
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2015
Matèries:
Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4345957/
https://ncbi.nlm.nih.gov/pubmed/25223731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12512
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars